Updated on 26 June 2015
36 deals were signed in 2014 in comparison to 16 in 2013
Singapore: According to research and consulting firm Global Data, number of deals struck by companies in the gene therapy segment has almost doubled in 2014. The number of deals announced 2014 sums up to 36 as compared to 16 in 2013.
The company's latest report states that merger and acquisition activity is typically low in the gene therapy field, as the technology remains highly experimental and the majority of products are in early-stage clinical development.
However, 2014 saw a change in this trend with some major deals being announced. Few of the noteworthy deals include Abbott Laboratories' $2.9 billion acquisition of CFR Pharmaceuticals (CFR), a Chilean biotechnology company developing gene therapeutics for alcoholism and chronic pain.
Bristol-Myers Squibb's inked a $1 billion licensing agreement with UniQure to develop S100AI, UniQure's Phase I candidate for congestive heart failure, representing the deal with the greatest financial impact so far this year. Voyager Therapeutics also signed an $845 million agreement with Genzyme to develop three Phase I programs concerning the central nervous system.
Mr Adam Dion, MS, GlobalData's Senior Industry Analyst, said, "Licensing and partnerships, together with capital raisings, have represented the largest number of gene therapy deals struck since 2009. Licensing deals have so far outpaced historical levels, with over $1.8 billion signed in 2015."